CAR-T Followed by Bispecific Antibodies

Abstract

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab). Phase: PHASE2 Status: RECRUITING Conditions: Large B-cell Lymphoma; DLBCL - Diffuse Large B Cell Lymphoma Interventions: mosunetuzumab; glofitamab; obinutuzumab

Keywords

Sources